CLDN6 CAR-T

BIOLOGICAL2 trials

Sponsors

BioNTech Cell & Gene Therapies GmbH, BioNTech SE

Conditions

Extragonadal Germ Cell TumorSolid TumorTesticular Germ Cell Tumor

Phase 1

A Clinical Study of the Safety and Effectiveness of an Investigational Cell Therapy Given With and Without an Investigational RNA-based Vaccine in Patients With Organ Tumors

Active, not recruitingNCT04503278

BioNTech Cell & Gene Therapies GmbHSolid Tumor

Start: 2020-09-16End: 2041-08-01Target: 214Updated: 2026-06-18

Phase 2

A Clinical Study Investigating the Therapeutic Effects and Safety of an Investigational Cell Therapy Given With and Without an Additional Investigational Product in Males With Testicular Cancer or a Form of Cancer That Developed From Sperm

WithdrawnNCT06940804

BioNTech SEExtragonadal Germ Cell Tumor, Testicular Germ Cell Tumor

Start: 2025-07-31End: 2042-06-30Updated: 2025-07-02

Related Papers

Fetal gut cell-like differentiation in esophageal adenocarcinoma defines a rare tumor subtype with therapeutically relevant claudin-6 positivity and SWI/SNF gene alteration.

2024-06-122 citations

CLDN6-specific CAR-T cells plus amplifying RNA vaccine in relapsed or refractory solid tumors: the phase 1 BNT211-01 trial

Nature Medicine2023-10-23210 citations

The tight junction protein claudin 6 is a potential target for patient-individualized treatment in esophageal and gastric adenocarcinoma and is associated with poor prognosis

Journal of Translational Medicine2023-08-1722 citations

CLDN6 CAR-T cell therapy of relapsed/refractory solid tumors ± a CLDN6-encoding mRNA vaccine: Dose escalation data from the BNT211-01 phase 1 trial using an automated product.

Journal of Clinical Oncology2023-06-018 citations

ATRT-17. CAR T CELL THERAPY TARGETING CLAUDIN-6 IS EFFECTIVE IN CELLULAR AND XENOGRAFT MODELS OF ATYPICAL TERATOID/RHABDOID TUMOR

Neuro-Oncology2023-06-01

351 Claudin 6 Expression in Atypical Teratoid/Rhabdoid Tumors is a Target for CAR-T Cell Therapy

Neurosurgery2023-03-161 citations

EXTH-85. TARGETING CLAUDIN 6 WITH CAR T CELL THERAPY FOR ATYPICAL TERATOID/RHABDOID TUMOR

Neuro-Oncology2022-11-01

Abstract CT002: BNT211: A Phase I trial to evaluate safety and efficacy of CLDN6 CAR-T cells and CARVac-mediated in vivo expansion in patients with CLDN6-positive advanced solid tumors

Cancer Research2022-06-1517 citations

958 BNT211: a phase I/II trial to evaluate safety and efficacy of CLDN6 CAR-T cells and vaccine-mediated in vivo expansion in patients with CLDN6-positive advanced solid tumors

2021-11-0117 citations